Non-muscle-invasive bladder cancer

What changed: Non-muscle-invasive bladder cancer

Cancer page →

Every dated change on the records linked to Non-muscle-invasive bladder cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Approval5Milestone5This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordNon-muscle-invasive bladder cancer
Facts on this page last checked
When this page itself was last checked or edited.

2026 · 1

2026ApprovalNadofaragene firadenovec
Nadofaragene firadenovec approved in EU
BCG-unresponsive NMIBC with CIS; 28 May 2026 (conditional)

2025 · 2

2024 · 2

2022 · 2

2020 · 1

2020MilestonePembrolizumab
Pembrolizumab approved for BCG-unresponsive carcinoma in situ
A milestone in how this cancer is treated.

1990 · 1

1990MilestoneIntravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)
BCG approved for carcinoma in situ of the bladder
A milestone in how this cancer is treated.

1976 · 1

1976MilestoneIntravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)
Morales reports intravesical BCG
A milestone in how this cancer is treated.